Structure Therapeutics to Present at Jefferies Healthcare Conference
31. Mai 2023 16:30 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
25. Mai 2023 16:30 ET
|
Structure Therapeutics Inc.
12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and...
Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference
18. Mai 2023 16:30 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, May 18, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...